Report ID: PMRREP34496
Report Type: Ongoing
Format: PPT*, PDF, EXCEL
Industry: Healthcare
The market for pulmonary embolism (PE) is expected to expand at a value based CAGR of 8.1% during 2024 – 2031, witnessing an increase in the estimated revenue of US$1.5 Bn in 2024 to US$3.5 Bn by 2031-end.
|
Report Attribute |
Details |
|
Market size value in 2024(E) |
US$1.5 Bn |
|
Revenue forecast in 2031(F) |
US$3.5 Bn |
|
CAGR (2024-2031) |
8.1% |
|
CAGR (2019-2023) |
7.8% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
Pulmonary embolism is increasingly becoming an area of concern and the unwavering number of patients living with risk factors further fuel the prevalence of the disease. In recent years, the global pulmonary embolism market is anticipated to grow rapidly, primarily driven by growing demand for effective PE treatment.
In the elderly, pulmonary illnesses can be lethal. The rising prevalence of this health problem among the elderly population is expected to drive demand. The market is likely to remain influenced as various technological breakthroughs are being incorporated into the healthcare industry in terms of diagnostics, healthcare, and medical treatment.
A large aging with increased risk factors like obesity, and chronic diseases largely contributes to the growing number of PE cases. Technological advancements in imaging techniques and minimally invasive catheter-directed thrombolysis procedures are leading to faster diagnosis, and more effective treatment.
The demand for minimally invasive procedures with lower complications, and faster recovery times is pushing the market towards innovative devices and techniques. Growing healthcare budgets globally are enabling greater investment in PE diagnosis and treatment.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Ascending Prevalence of Cancers
The global pulmonary embolism market is driven by an increase in prevalence of cancer. Patients who are receiving chemotherapy or who have a family history of the condition are at the greatest risk, which is expected to increase demand for pulmonary embolism medications.
The industry is expected to develop in response to the growing number of cancer patients worldwide. The World Health Organization reported approximately 10 million cancer-caused deaths in 2020 and the number continues to rise high.
Investments Flowing into Healthcare Infrastructure
Increasing Investments in healthcare infrastructure is another strong factor bolstering the market growth. Rising healthcare expenditure by individuals and governments alike, as well as growing sophistication of the healthcare infrastructure play an instrumental role in the market build-up.
Sizeable Population with Tobacco Smoking Addiction
Long-term smoking addiction is one of the leading causes of lung illnesses, also including pulmonary embolism. The stress levels of this population base have risen significantly as a result of growing urbanization, industrialization, increased work pressure, and busier lifestyles.
This scenario is expected to result in an increase in smoking addiction, potentially leading to higher sales potential in the pulmonary embolism market.
Limited Awareness About Causes, Symptoms, and Available Treatments
There is a considerable lack of awareness and knowledge about pulmonary embolism among both the general population and healthcare professionals. This can result in delayed recognition of symptoms, leading to delayed diagnosis, medical attention, and appropriate treatment.
High Treatment Costs
The high cost of PE medications, and procedures put a substantial strain on healthcare budgets. On the other hand, high treatment costs associated with PE are prompting healthcare providers to focus on cost-effective strategies, and value-based care models.
Rising R&D Activity Around PE, and Related Conditions
The pulmonary embolism market size will inflate with an increase in the number of R&D activities surrounding the causes, potential treatments, therapeutic solutions, and diagnostics for PE.
This will create beneficial opportunities for the global pulmonary embolism market growth. Rising drug approvals, and mew launches in treatments and devices segments will further propel the market’s opportunistic potential.
The Most Widely Prevalent PE Symptom of Shortness of Breath
Shortness of breath is often the most common and concerning symptom of pulmonary embolism. Shortness of breath occurs in a large percentage of PE cases, making it a strong indicator for further investigation.
Sudden or worsening shortness of breath can be a red flag for a serious condition like PE. While other symptoms like chest pain, and cough are
CTPA to be the Gold Standard for PE Diagnosis
In diagnosing PE, CT pulmonary angiography (CTPA) is the dominant diagnostic tool for its higher accuracy, and speed. CTPA provides detailed images of blood vessels in the lungs, allowing for precise identification of blood clots. Moreover, results are available quickly, enabling prompt treatment decisions.
The CTPA diagnosis is less invasive than procedures like pulmonary angiography, thereby reducing discomfort and risk for patients. However, other tests play crucial roles as well. Others prominently include ventilation perfusion scan (V/Q scan), D-Dimer test, and other tests like ECG, chest X-rays, and venous ultrasound.
The choice of diagnostic tool depends on factors like patient history, clinical presentation, and potential risks. CTPA remains the gold standard due to its accuracy and speed, but other tests play a valuable role in a comprehensive diagnostic approach.
PE Medications Most Sought-After PE Treatment
In pulmonary embolism treatment, medications dominate the market segment due to their effectiveness, and wider applicability. Medications like blood thinners (anticoagulants) are the mainstay of PE treatment, preventing further clot formation, and promoting clot breakdown.
These medications cater to a large range of PE severity levels by ensuring minimal invasion, and long-term management. Other treatment segments continue to grow as well, like mechanical devices, and surgery, for more severe cases of PE.
Hospitals Wear the Major End User Tag
Hospitals continue to dominate the adoption of pulmonary embolism treatment solutions. Most PE cases require initial hospitalization for diagnosis, monitoring, and treatment initiation with medications or procedures like thrombolysis.
Hospitals have specialists, and equipment necessary for accurate diagnosis and complex PE management. Hospitals provide crucial post-procedural care for patients undergoing surgery or mechanical thrombectomy.
Hospital Pharmacies Top Distribution
Hospital pharmacies hold the dominant position as a key end user category in the pulmonary embolism market. Many PE medications, especially those for initial treatment, are powerful drugs requiring close monitoring.
Hospital pharmacies control access and ensure proper administration. They work with doctors to ensure patients receive the correct medication dosage and address potential drug interactions.
Hospitals often stock a wider range of PE medications to cater to diverse patient needs, and specific treatment protocols. On the other side, retail pharmacies are set to emerge lucrative in the upcoming years, in long-term PE medication management.
North America Secures the Top Spot
North America stands the tallest as it is the largest revenue contributing region in the market for pulmonary embolism treatment. North America currently holds a dominant share, majorly attributing to the presence of key industry players, and growing disease prevalence in the region.
Factors like an aging population, increased obesity rates, and higher incidence of chronic diseases contribute to a larger number of PE cases in this region.
Well-developed healthcare systems with access to advanced diagnostic tools and treatment options also play a pivotal role in strengthening the globally leading position of North America.
Major pharmaceutical and medical device companies involved in PE treatment are headquartered in North America, pushing market growth. Higher per capita healthcare expenditure, and pacing investments in PE diagnosis and treatment further uphold the region’s leadership position.
May 2024
A new radiology procedure was conducted for treating blood clots in the lungs. It discusses a 55-year-old patient who was treated for pulmonary thromboembolism at BMHRC. The clot was dissolved using medication delivered through a catheter. This procedure is called catheter-directed thrombolysis (CDT), promising a less invasive way of PE treatment.
May 2024
AngioDynamics announced the confirmation received on its AlphaVac device in terms of safety and effectiveness in acute pulmonary embolism treatment. During a trial, it significantly improved heart function and reduced clot burden in patients, way beyond expectations. The company claims the device is promising for treating PE - with minimal complications.
January 2024
A new minimally invasive procedure for removing blood clots that was performed for the first time in India, at Medanta Hospital, Gurugram. The technology utilizes an AI-driven device called the Penumbra Flash 12 F Catheter. This catheter offers several advantages over traditional methods, including reduced complications, and blood loss. Doctors view this technology as a significant advancement in PE treatment.
August 2021
Boston Scientific declared the initiation of a randomized controlled trial for its EkoSonic™ Endovascular System targeting patients of PE, and peripheral artery occlusions. The device makes combined use of ultrasound radiation, and a thrombolytic medication to achieve breakup of blood clots, and restored blood flow – promising reduced treatment time, reduced recommended thrombolytic dose, and lowered bleeding risk.
2020-2024
Various studies demonstrated the connection between COVID-19, and pulmonary embolism to find that the former could significantly increase a person's risk of developing a PE or a blood clot that lodges in the lungs and can be fatal. People with severe COVID-19 were at a particularly high risk of developing PE.
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Symptom
By Diagnosis
By Treatment
By End User
By Distribution Channel
By Region
For report customisation and delivery information contact our sales representative.
The market is valued at about US$1.5 billion as of 2024 and is expected to grow strongly in the years to come.
Growth is driven by rising incidence rates, advancements in diagnostics and treatment, and increasing awareness.
North America, especially the US, leads the market, followed by Europe. The Asia Pacific region is the fastest growing.
Treatments include anticoagulants (heparin, warfarin), thrombolytic therapy, surgical interventions, and direct oral anticoagulants (DOACs).
Some of the key players are Bayer AG, Johnson & Johnson, Boehringer Ingelheim, Pfizer Inc., and Bristol-Myers Squibb.
